{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T11:02:24Z","timestamp":1776942144282,"version":"3.51.4"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:00:00Z","timestamp":1685923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T00:00:00Z","timestamp":1685923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Next-Generation Sequencing (NGS)-based testing in cancer patients has led to increased detection of variants of uncertain significance (VUS). VUS are genetic variants whose impact on protein function is unknown. VUS pose a challenge to clinicians and patients due to uncertainty regarding their cancer predisposition risk. Paucity of data exists on the pattern of VUS in under-represented populations. This study describes the frequency of germline VUS and clinico-pathological features in Sri Lankan hereditary breast cancer patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data of 72 hereditary breast cancer patients who underwent NGS-based testing between January 2015 and December 2021 were maintained prospectively in a database and analyzed retrospectively. Data were subjected to bioinformatics analysis and variants were classified according to international guidelines.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Germline variants were detected in 33\/72(45.8%) patients, comprising 16(48.5%) pathogenic\/likely pathogenic variants and 17(51.5%) VUS. Distribution of VUS in breast cancer predisposing genes were :<jats:italic>APC<\/jats:italic>:1(5.8%), <jats:italic>ATM<\/jats:italic>:2(11.7%), <jats:italic>BRCA<\/jats:italic><jats:italic>1<\/jats:italic>:1(5.8%), <jats:italic>BRCA<\/jats:italic><jats:italic>2<\/jats:italic>:5(29.4%), <jats:italic>BRIP<\/jats:italic><jats:italic>1<\/jats:italic>:1(5.8%), <jats:italic>CDKN<\/jats:italic><jats:italic>2A<\/jats:italic>:1(5.8%), <jats:italic>CHEK<\/jats:italic><jats:italic>2<\/jats:italic>:2(11.7%), <jats:italic>FANC<\/jats:italic><jats:italic>1<\/jats:italic>:1(5.8%), <jats:italic>MET<\/jats:italic>:1(5.8%), <jats:italic>STK<\/jats:italic><jats:italic>11<\/jats:italic>:1(5.8%), <jats:italic>NF<\/jats:italic><jats:italic>2<\/jats:italic>:1(5.8%). Mean age at cancer diagnosis in patients with VUS was 51.2 years. Most common tumour histopathology was ductal carcinoma 11(78.6%). 50% of tumours in patients having VUS in <jats:italic>BRCA<\/jats:italic><jats:italic>1\/2<\/jats:italic> genes were hormone receptor negative. 73.3% patients had family history of breast cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>A significant portion of patients had a germline VUS. Highest frequency was in <jats:italic>BRCA<\/jats:italic><jats:italic>2<\/jats:italic> gene. Majority had family history of breast cancer. This highlights the need to undertake functional genomic studies to determine the biological effects of VUS and identify potentially clinically actionable variants that would be useful for decision-making and patient management.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13104-023-06365-4","type":"journal-article","created":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T16:02:16Z","timestamp":1685980936000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Germline variants of uncertain significance, their frequency, and clinico-pathological features in a cohort of Sri Lankan patients with hereditary breast cancer"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0205-2608","authenticated-orcid":false,"given":"Kawmadi","family":"Gunawardena","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0994-6954","authenticated-orcid":false,"given":"Nirmala D.","family":"Sirisena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gayani","family":"Anandagoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nilaksha","family":"Neththikumara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3264-6856","authenticated-orcid":false,"given":"Vajira H.W.","family":"Dissanayake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,5]]},"reference":[{"key":"6365_CR1","unstructured":"International Agency for Research on Cancer. (2008). GLOBOCAN 2008: cancer incidence and mortality worldwide in 2008. http:\/\/globocan.iarc.fr\/"},{"issue":"1","key":"6365_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-018-4408-4","volume":"18","author":"A Fernando","year":"2018","unstructured":"Fernando A, Jayarajah U, Prabashani S, Fernando EA, Seneviratne SA. Incidence trends and patterns of breast cancer in Sri Lanka: an analysis of the national cancer database. BMC Cancer. 2018;18(1):1\u20136. https:\/\/doi.org\/10.1186\/s12885-018-4408-4.","journal-title":"BMC Cancer"},{"key":"6365_CR3","doi-asserted-by":"crossref","unstructured":"Walsh T, Lee MK, Casadei S, Thornton AM, Stray SM, Pennil C, \u2026, King MC. (2010). Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proceedings of the National Academy of Sciences, 107(28), 12629\u201312633.https:\/\/doi.org\/10.1073\/pnas.1007983107.","DOI":"10.1073\/pnas.1007983107"},{"issue":"4988","key":"6365_CR4","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1126\/science.2270482","volume":"250","author":"JM Hall","year":"1990","unstructured":"Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, King MC. Linkage of early-onset familial breast cancer to chromosome 17q21. Science. 1990;250(4988):1684\u20139. https:\/\/doi.org\/10.1126\/science.2270482.","journal-title":"Science"},{"issue":"5181","key":"6365_CR5","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1126\/science.8091231","volume":"265","author":"R Wooster","year":"1994","unstructured":"Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, \u2026, Stratton MR. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994;265(5181):2088\u201390. https:\/\/doi.org\/10.1126\/science.8091231.","journal-title":"Science"},{"issue":"23","key":"6365_CR6","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1056\/NEJMsr1501341","volume":"372","author":"DF Easton","year":"2015","unstructured":"Easton DF, Pharoah PD, Antoniou AC, Tischkowitz M, Tavtigian SV, Nathanson KL, \u2026, Foulkes WD. Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med. 2015;372(23):2243\u201357. https:\/\/doi.org\/10.1056\/NEJMsr1501341.","journal-title":"N Engl J Med"},{"issue":"5","key":"6365_CR7","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, \u2026, Rehm HL. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Sci. 2015;17(5):405\u201323. https:\/\/doi.org\/10.1038\/gim.2015.30.","journal-title":"Genet Sci"},{"issue":"10","key":"6365_CR8","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1245\/s10434-017-5963-7","volume":"24","author":"E O\u2019leary","year":"2017","unstructured":"O\u2019leary E, Iacoboni D, Holle J, Michalski ST, Esplin ED, Yang S, Ouyang K. Expanded gene panel use for women with breast cancer: identification and intervention beyond breast cancer risk. Ann Surg Oncol. 2017;24(10):3060\u20136. https:\/\/doi.org\/10.1245\/s10434-017-5963-7.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"6365_CR9","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1200\/JCO.18.01631","volume":"37","author":"PD Beitsch","year":"2019","unstructured":"Beitsch PD, Whitworth PW, Hughes K, Patel R, Rosen B, Compagnoni G, \u2026, Nussbaum RL. Underdiagnosis of hereditary breast cancer: are genetic testing guidelines a tool or an obstacle? J Clin Oncol. 2019;37(6):453. https:\/\/doi.org\/10.1200%2FJCO.18.01631.","journal-title":"J Clin Oncol"},{"issue":"8","key":"6365_CR10","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1001\/jamaoncol.2018.0644","volume":"4","author":"AW Kurian","year":"2018","unstructured":"Kurian AW, Ward KC, Hamilton AS, Deapen DM, Abrahamse P, Bondarenko I, \u2026, Katz SJ. Uptake, results, and outcomes of germline multiple-gene sequencing after diagnosis of breast cancer. JAMA Oncol. 2018;4(8):1066\u201372. https:\/\/doi.org\/10.1001\/jamaoncol.2018.0644.","journal-title":"JAMA Oncol"},{"issue":"1","key":"6365_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-015-1934-1","volume":"15","author":"BK Eccles","year":"2015","unstructured":"Eccles BK, Copson E, Maishman T, Abraham JE, Eccles DM. Understanding of BRCA VUS genetic results by breast cancer specialists. BMC Cancer. 2015;15(1):1\u20139. https:\/\/doi.org\/10.1186\/s12885-015-1934-1.","journal-title":"BMC Cancer"},{"issue":"6","key":"6365_CR12","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/cge.12563","volume":"88","author":"CL Scherr","year":"2015","unstructured":"Scherr CL, Lindor NM, Malo TL, Couch FJ, Vadaparampil ST. Genetic counselors\u2019 practices and confidence regarding variant of uncertain significance results and reclassification from BRCA testing. Clin Genet. 2015;88(6):523\u20139. https:\/\/doi.org\/10.1111\/cge.12563.","journal-title":"Clin Genet"},{"issue":"10","key":"6365_CR13","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1093\/annonc\/mdv278","volume":"26","author":"DM Eccles","year":"2015","unstructured":"Eccles DM, Mitchell G, Monteiro ANA, Schmutzler R, Couch FJ, Spurdle AB, \u2026, Goldgar D. BRCA1 and BRCA2 genetic testing\u2014pitfalls and recommendations for managing variants of uncertain clinical significance. Ann Oncol. 2015;26(10):2057\u201365. https:\/\/doi.org\/10.1093\/annonc\/mdv278.","journal-title":"Ann Oncol"},{"issue":"8","key":"6365_CR14","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1002\/humu.23555","volume":"39","author":"A Henrie","year":"2018","unstructured":"Henrie A, Hemphill SE, Ruiz-Schultz N, Cushman B, DiStefano MT, Azzariti D, \u2026, Eilbeck K. ClinVar miner: demonstrating utility of a web\u2010based tool for viewing and filtering ClinVar data. Hum Mutat. 2018;39(8):1051\u201360. https:\/\/doi.org\/10.1002\/humu.23555.","journal-title":"Hum Mutat"},{"issue":"1","key":"6365_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-022-07383-1","volume":"12","author":"RSC Guindalini","year":"2022","unstructured":"Guindalini RSC, Viana DV, Kitajima JPFW, Rocha VM, L\u00f3pez RVM, Zheng Y, \u2026, Folgueira MAAK. Detection of germline variants in brazilian breast cancer patients using multigene panel testing. Sci Rep. 2022;12(1):1\u201312. https:\/\/doi.org\/10.1038\/s41598-022-07383-1.","journal-title":"Sci Rep"},{"issue":"1","key":"6365_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/npjgenmed.2015.3","volume":"1","author":"ES Wong","year":"2016","unstructured":"Wong ES, Shekar S, Met-Domestici M, Chan C, Sze M, Yap YS, \u2026, Lee AS. Inherited breast cancer predisposition in Asians: multigene panel testing outcomes from Singapore. NPJ genomic medicine. 2016;1(1):1\u20139. https:\/\/doi.org\/10.1038\/npjgenmed.2015.3.","journal-title":"NPJ genomic medicine"},{"issue":"1","key":"6365_CR17","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/35094067","volume":"1","author":"R Fodde","year":"2001","unstructured":"Fodde R, Smits R, Clevers H. APC, signal transduction and genetic instability in colorectal cancer. Nat Rev Cancer. 2001;1(1):55\u201367. https:\/\/doi.org\/10.1038\/35094067.","journal-title":"Nat Rev Cancer"},{"issue":"12","key":"6365_CR18","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.neo.2019.09.002","volume":"21","author":"CD Stefanski","year":"2019","unstructured":"Stefanski CD, Keffler K, McClintock S, Milac L, Prosperi JR. APC loss affects DNA damage repair causing doxorubicin resistance in breast cancer cells. Neoplasia. 2019;21(12):1143\u201350. https:\/\/doi.org\/10.1016\/j.neo.2019.09.002.","journal-title":"Neoplasia"},{"issue":"1","key":"6365_CR19","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/jcb.23350","volume":"113","author":"TD King","year":"2012","unstructured":"King TD, Suto MJ, Li Y. The wnt\/\u03b2-catenin signaling pathway: a potential therapeutic target in the treatment of triple negative breast cancer. J Cell Biochem. 2012;113(1):13\u20138. https:\/\/doi.org\/10.1002\/jcb.23350.","journal-title":"J Cell Biochem"},{"issue":"3","key":"6365_CR20","first-page":"215","volume":"12","author":"T S\u00f8rlie","year":"1998","unstructured":"S\u00f8rlie T, Bukholm I, B\u00f8rresen-Dale AL. Truncating somatic mutation in exon 15 of the APC gene is a rare event in human breast carcinomas. Mutations in brief no. 179. Online. Hum Mutat. 1998;12(3):215\u20135. https:\/\/europepmc.org\/article\/med\/10660330.","journal-title":"Hum Mutat"},{"issue":"6","key":"6365_CR21","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1016\/s0002-9440(10)65072-9","volume":"156","author":"K Furuuchi","year":"2000","unstructured":"Furuuchi K, Tada M, Yamada H, Kataoka A, Furuuchi N, Hamada JI, \u2026, Moriuchi T. Somatic mutations of the APC gene in primary breast cancers. Am J Pathol. 2000;156(6):1997\u20132005. https:\/\/doi.org\/10.1016\/s0002-9440(10)65072-9.","journal-title":"Am J Pathol"},{"issue":"22","key":"6365_CR22","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1093\/jnci\/92.22.1805","volume":"92","author":"K Kawakami","year":"2000","unstructured":"Kawakami K, Brabender J, Lord RV, Groshen S, Greenwald BD, Krasna MJ, \u2026, Meltzer SJ. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst. 2000;92(22):1805\u201311. https:\/\/doi.org\/10.1093\/jnci\/92.22.1805.","journal-title":"J Natl Cancer Inst"},{"key":"6365_CR23","unstructured":"Usadel, H., Brabender, J., Danenberg, K. D., Jer\u00f3nimo, C., Harden, S., Engles, J.,\u2026 Sidransky, D. (2002). Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer research, 62(2),371\u2013375. https:\/\/aacrjournals.org\/cancerres\/article\/62\/2\/371\/509230\/Quantitative-Adenomatous-Polyposis-Coli-Promoter."},{"issue":"6","key":"6365_CR24","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1016\/0016-5085(94)90818-4","volume":"107","author":"SM Powell","year":"1994","unstructured":"Powell SM, Papadopoulos N, Kinzler KW, Smolinski KN, Meltzer SJ. APC gene mutations in the mutation cluster region are rare in esophageal cancers. Gastroenterology. 1994;107(6):1759\u201363. https:\/\/doi.org\/10.1016\/0016-5085(94)90818-4.","journal-title":"Gastroenterology"},{"issue":"1","key":"6365_CR25","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/path.1884","volume":"208","author":"G Cl\u00e9ment","year":"2006","unstructured":"Cl\u00e9ment G, Braunschweig R, Pasquier N, Bosman FT, Benhattar J. Methylation of APC, TIMP3, and TERT: a new predictive marker to distinguish Barrett\u2019s oesophagus patients at risk for malignant transformation. J Pathology: J Pathological Soc Great Br Irel. 2006;208(1):100\u20137. https:\/\/doi.org\/10.1002\/path.1884.","journal-title":"J Pathology: J Pathological Soc Great Br Irel"},{"issue":"1","key":"6365_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-9-24","volume":"9","author":"M Zare","year":"2009","unstructured":"Zare M, Jazii FR, Alivand MR, Nasseri NK, Malekzadeh R, Yazdanbod M. Qualitative analysis of adenomatous Polyposis Coli promoter: hypermethylation, engagement and effects on survival of patients with esophageal cancer in a high risk region of the world, a potential molecular marker. BMC Cancer. 2009;9(1):1\u201312. https:\/\/doi.org\/10.1186\/1471-2407-9-24.","journal-title":"BMC Cancer"},{"key":"6365_CR27","doi-asserted-by":"crossref","unstructured":"Karachaliou, G. S., Alkallas, R., Carroll, S. B., Caressi, C., Zakria, D., Patel,N. M., \u2026 Moschos, S. J. (2022). The clinical significance of adenomatous polyposis coli (APC) and catenin Beta 1 (CTNNB1) genetic aberrations in patients with melanoma.BMC cancer, 22(1), 1\u201314. https:\/\/doi.org\/10.1186\/s12885-021-08908-z.","DOI":"10.1186\/s12885-021-08908-z"},{"issue":"30","key":"6365_CR28","doi-asserted-by":"publisher","first-page":"5215","DOI":"10.1038\/sj.onc.1207647","volume":"23","author":"J Worm","year":"2004","unstructured":"Worm J, Christensen C, Gr\u00f8nb\u00e6k K, Tulchinsky E, Guldberg P. Genetic and epigenetic alterations of the APC gene in malignant melanoma. Oncogene. 2004;23(30):5215\u201326. https:\/\/doi.org\/10.1038\/sj.onc.1207647.","journal-title":"Oncogene"},{"key":"6365_CR29","doi-asserted-by":"crossref","unstructured":"Uchino, S., Ishikawa, H., Miyauchi, A., Hirokawa, M., Noguchi, S., Ushiama, M., \u2026Sakai, T. (2016). Age-and gender-specific risk of thyroid cancer in patients with familial adenomatous polyposis. The Journal of Clinical Endocrinology & Metabolism, 101(12), 4611\u20134617. https:\/\/doi.org\/10.1210\/jc.2016-2043.","DOI":"10.1210\/jc.2016-2043"},{"key":"6365_CR30","doi-asserted-by":"crossref","unstructured":"Jarrar, A. M., Milas, M., Mitchell, J., Laguardia, L., Berber, E., Siperstein, A.,\u2026 Church, J. M. (2011). Screening for thyroid cancer in patients with familial adenomatous polyposis. Annals of surgery, 253(3), 515\u2013521. https:\/\/doi.org\/10.1097\/SLA.0b013e3181fcba8a.","DOI":"10.1097\/SLA.0b013e3181fcba8a"},{"key":"6365_CR31","doi-asserted-by":"crossref","unstructured":"Renwick, A., Thompson, D., Seal, S., Kelly, P., Chagtai, T., Ahmed, M., \u2026 Rahman,N. (2006). ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nature genetics, 38(8), 873\u2013875. https:\/\/doi.org\/10.1038\/ng1837.","DOI":"10.1038\/ng1837"},{"key":"6365_CR32","doi-asserted-by":"crossref","unstructured":"Easton, D. F., Pharoah, P. D., Antoniou, A. C., Tischkowitz, M., Tavtigian, S. V.,Nathanson, K. L., \u2026 Foulkes, W. D. (2015). Gene-panel sequencing and the prediction of breast-cancer risk. New England Journal of Medicine, 372(23), 2243\u20132257. https:\/\/doi.org\/10.1056\/NEJMsr1501341.","DOI":"10.1056\/NEJMsr1501341"},{"key":"6365_CR33","unstructured":"Bullrich, F., Rasio, D., Kitada, S., Starostik, P., Kipps, T., Keating, M., \u2026 Croce,C. M. (1999). ATM mutations in B-cell chronic lymphocytic leukemia. Cancer research, 59(1), 24\u201327. https:\/\/aacrjournals.org\/cancerres\/article\/59\/1\/24\/505073\/ATM-Mutations-in-B-Cell-Chronic-Lymphocytic."},{"issue":"2","key":"6365_CR34","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1182\/blood.V94.2.748","volume":"94","author":"C Schaffner","year":"1999","unstructured":"Schaffner C, Stilgenbauer S, Rappold GA, D\u00f6hner H, Lichter P. Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia. Blood The Journal of the American Society of Hematology. 1999;94(2):748\u201353. https:\/\/doi.org\/10.1182\/blood.V94.2.748.","journal-title":"Blood The Journal of the American Society of Hematology"},{"key":"6365_CR35","doi-asserted-by":"crossref","unstructured":"Guarini, A., Marinelli, M., Tavolaro, S., Bellacchio, E., Magliozzi, M., Chiaretti,S., \u2026 Fo\u00e0, R. (2012). ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression. Haematologica, 97(1), 47. https:\/\/doi.org\/10.3324%2Fhaematol.2011.049270.","DOI":"10.3324\/haematol.2011.049270"},{"key":"6365_CR36","doi-asserted-by":"crossref","unstructured":"Rose-Zerilli, M. J., Forster, J., Parker, H., Parker, A., Rodr\u00edguez, A. E., Chaplin,T., \u2026 Strefford, J. C. (2014). ATM mutation rather than BIRC3 deletion and\/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial. haematologica, 99(4), 736. https:\/\/doi.org\/10.3324%2Fhaematol.2013.098574.","DOI":"10.3324\/haematol.2013.098574"},{"issue":"6","key":"6365_CR37","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/1097-0215","volume":"88","author":"P Maillet","year":"2000","unstructured":"Maillet P, Chappuis PO, Vaudan G, Dobbie Z, M\u00fcller H, Hutter P, Sappino AP. A polymorphism in the ATM gene modulates the penetrance of hereditary non-polyposis colorectal cancer. Int J Cancer. 2000;88(6):928\u201331. https:\/\/doi.org\/10.1002\/1097-0215. :6%3C928::AID-IJC14%3E3.0.CO;2-P.","journal-title":"Int J Cancer"},{"key":"6365_CR38","doi-asserted-by":"crossref","unstructured":"Vitiello, P. P., Martini, G., Mele, L., Giunta, E. F., De Falco, V., Ciardiello, D.,\u2026 Martinelli, E. (2021). Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer. Journal of Experimental & Clinical Cancer Research, 40(1), 1\u201315. https:\/\/doi.org\/10.1186\/s13046-020-01811-8.","DOI":"10.1186\/s13046-020-01811-8"},{"issue":"1","key":"6365_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-7-152","volume":"7","author":"B Friedenson","year":"2007","unstructured":"Friedenson B. The BRCA1\/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers. BMC Cancer. 2007;7(1):1\u201311. https:\/\/doi.org\/10.1186\/1471-2407-7-152.","journal-title":"BMC Cancer"},{"issue":"1","key":"6365_CR40","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/MAJ.0b013e3181bedb74","volume":"339","author":"M Cole","year":"2010","unstructured":"Cole M, Strair R. Acute myelogenous leukemia and myelodysplasia secondary to breast cancer treatment: case studies and literature review. Am J Med Sci. 2010;339(1):36\u201340. https:\/\/doi.org\/10.1097\/MAJ.0b013e3181bedb74.","journal-title":"Am J Med Sci"},{"issue":"6","key":"6365_CR41","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1080\/07357900600894872","volume":"24","author":"A Fruscalzo","year":"2006","unstructured":"Fruscalzo A, Damante G, Calcagno A, Di Loreto C, Marchesoni D. Four primary malignancies successively occurred in a BRCA2 mutation carrier: a case report. Cancer Invest. 2006;24(6):611\u20134. https:\/\/doi.org\/10.1080\/07357900600894872.","journal-title":"Cancer Invest"},{"issue":"4","key":"6365_CR42","first-page":"765","volume":"47","author":"MJ Hall","year":"2006","unstructured":"Hall MJ, Li L, Wiernik PH, Olopade OI. BRCA2 mutation and the risk of hematologic malignancy. Leukemia & lymphoma. 2006;47(4):765\u20137. https:\/\/europepmc.org\/article\/med\/16886281.","journal-title":"Leukemia & lymphoma"},{"key":"6365_CR43","doi-asserted-by":"crossref","unstructured":"Beiner, M. E., Finch, A., Rosen, B., Lubinski, J., Moller, P., Ghadirian, P., \u2026 Hereditary Ovarian Cancer Clinical Study Group. (2007). The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. Gynecologic oncology, 104(1), 7\u201310. https:\/\/doi.org\/10.1016\/j.ygyno.2006.08.004.","DOI":"10.1016\/j.ygyno.2006.08.004"},{"key":"6365_CR44","doi-asserted-by":"crossref","unstructured":"Segev, Y., Iqbal, J., Lubinski, J., Gronwald, J., Lynch, H. T., Moller, P., \u2026 Hereditary Breast Cancer Study Group. (2013). The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study. Gynecologic oncology, 130(1), 127\u2013131. https:\/\/doi.org\/10.1016\/j.ygyno.2013.03.027.","DOI":"10.1016\/j.ygyno.2013.03.027"},{"key":"6365_CR45","doi-asserted-by":"crossref","unstructured":"Shu, C. A., Pike, M. C., Jotwani, A. R., Friebel, T. M., Soslow, R. A., Levine, D.A., \u2026 Kauff, N. D. (2016). Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA mutations. JAMA oncology, 2(11), 1434\u20131440. https:\/\/doi.org\/10.1001\/jamaoncol.2016.1820.","DOI":"10.1001\/jamaoncol.2016.1820"},{"key":"6365_CR46","doi-asserted-by":"crossref","unstructured":"Weber-Lassalle, N., Hauke, J., Ramser, J., Richters, L., Gross, E., Bl\u00fcmcke, B., \u2026Hahnen, E. (2018). BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer. Breast Cancer Research, 20(1), 1\u20136. https:\/\/doi.org\/10.1186\/s13058-018-0935-9.","DOI":"10.1186\/s13058-018-0935-9"},{"issue":"1","key":"6365_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13048-020-00654-3","volume":"13","author":"M Suszynska","year":"2020","unstructured":"Suszynska M, Ratajska M, Kozlowski P. BRIP1, RAD51C, and RAD51D mutations are associated with high susceptibility to ovarian cancer: mutation prevalence and precise risk estimates based on a pooled analysis of ~ 30,000 cases. J ovarian Res. 2020;13(1):1\u201311. https:\/\/doi.org\/10.1186\/s13048-020-00654-3.","journal-title":"J ovarian Res"},{"issue":"1","key":"6365_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12881-019-0812-0","volume":"20","author":"M Ali","year":"2019","unstructured":"Ali M, Delozier CD, Chaudhary U. BRIP-1 germline mutation and its role in colon cancer: presentation of two case reports and review of literature. BMC Med Genet. 2019;20(1):1\u20135. https:\/\/doi.org\/10.1186\/s12881-019-0812-0.","journal-title":"BMC Med Genet"},{"key":"6365_CR49","doi-asserted-by":"crossref","unstructured":"Mart\u00edn-Morales, L., Garre, P., Lorca, V., Cazorla, M., Llovet, P., Bando, I., \u2026 Cald\u00e9s,T. (2021). BRIP1, a gene potentially implicated in Familial Colorectal Cancer Type X. Cancer Prevention Research, 14(2), 185\u2013194. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-20-0316.","DOI":"10.1158\/1940-6207.CAPR-20-0316"},{"issue":"1","key":"6365_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-017-3244-2","volume":"17","author":"M Spitzwieser","year":"2017","unstructured":"Spitzwieser M, Entfellner E, Werner B, Pulverer W, Pfeiler G, Hacker S, Cichna-Markl M. Hypermethylation of CDKN2A exon 2 in tumor, tumor-adjacent and tumor-distant tissues from breast cancer patients. BMC Cancer. 2017;17(1):1\u201316. https:\/\/doi.org\/10.1186\/s12885-017-3244-2.","journal-title":"BMC Cancer"},{"issue":"1","key":"6365_CR51","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s12282-018-0894-0","volume":"26","author":"A Aftab","year":"2019","unstructured":"Aftab A, Shahzad S, Hussain HMJ, Khan R, Irum S, Tabassum S. CDKN2A\/P16INK4A variants association with breast cancer and their in-silico analysis. Breast Cancer. 2019;26(1):11\u201328. https:\/\/doi.org\/10.1007\/s12282-018-0894-0.","journal-title":"Breast Cancer"},{"key":"6365_CR52","doi-asserted-by":"crossref","unstructured":"Cybulski, C., Gorski, B., Huzarski, T., Masoj\u0107, B., Mierzejewski, M., D\u0119bniak, T.,\u2026 Lubi\u0144ski, J. (2004). CHEK2 is a multiorgan cancer susceptibility gene. The American Journal of Human Genetics, 75(6), 1131\u20131135. https:\/\/doi.org\/10.1086\/426403.","DOI":"10.1086\/426403"},{"issue":"28","key":"6365_CR53","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1200\/JCO.2010.34.0778","volume":"29","author":"C Cybulski","year":"2011","unstructured":"Cybulski C, Wokolorczyk D, Jakubowska A, et al. Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. J Clin Oncol. 2011;29(28):3747\u201352.","journal-title":"J Clin Oncol"},{"key":"6365_CR54","doi-asserted-by":"crossref","unstructured":"Gordiev, M., Brovkina, O., Shigapova, L. H., Shagimardanova, E., Enikeev, R. F., Nikitin,A., \u2026 Sakaeva, D. (2019). Heterozygous mutation in fanconi anemia genes associated with hereditary breast cancer. Annals of Oncology, 30, iii10. https:\/\/doi.org\/10.1093\/annonc\/mdz095.028.","DOI":"10.1093\/annonc\/mdz095.028"},{"issue":"4","key":"6365_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/bcr2617","volume":"12","author":"S Gastaldi","year":"2010","unstructured":"Gastaldi S, Comoglio PM, Trusolino L. The Met oncogene and basal-like breast cancer: another culprit to watch out for? Breast Cancer Res. 2010;12(4):1\u201310. https:\/\/doi.org\/10.1186\/bcr2617.","journal-title":"Breast Cancer Res"},{"key":"6365_CR56","doi-asserted-by":"publisher","unstructured":"Clements A, Robison K, Granai C, Steinhoff MM, Scalia-Wilbur J, Moore RG. A case of Peutz-Jeghers syndrome with breast cancer, bilateral sex cord tumor with annular tubules, and adenoma malignum caused by STK11 gene mutation. Int J Gynecologic Cancer. 2009;19(9). https:\/\/doi.org\/10.1111\/IGC.0b013e3181ae3f71.","DOI":"10.1111\/IGC.0b013e3181ae3f71"},{"issue":"5","key":"6365_CR57","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/onc.2015.125","volume":"35","author":"AM Petrilli","year":"2016","unstructured":"Petrilli AM, Fern\u00e1ndez-Valle C. Role of Merlin\/NF2 inactivation in tumor biology. Oncogene. 2016;35(5):537\u201348. https:\/\/doi.org\/10.1038\/onc.2015.125.","journal-title":"Oncogene"},{"issue":"4","key":"6365_CR58","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1093\/hmg\/3.4.565","volume":"3","author":"H Arakawa","year":"1994","unstructured":"Arakawa H, Hayashl N, Nagase H, Ogawa M, Nakamura Y. Alternative splicing of the NF2 gene and its mutation analysis of breast and colorectal cancers. Hum Mol Genet. 1994;3(4):565\u20138. https:\/\/doi.org\/10.1093\/hmg\/3.4.565.","journal-title":"Hum Mol Genet"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-023-06365-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13104-023-06365-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-023-06365-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,5]],"date-time":"2023-06-05T16:02:33Z","timestamp":1685980953000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/s13104-023-06365-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,5]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["6365"],"URL":"https:\/\/doi.org\/10.1186\/s13104-023-06365-4","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,5]]},"assertion":[{"value":"21 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All procedures performed in the study involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Ethical approval for the study was obtained from the Ethics Review Committee, Faculty of Medicine, University of Colombo, Sri Lanka [EC-13-182]. Informed written consent was obtained from all patients who underwent germline genetic testing for the participation in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not Applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"95"}}